Ensign Peak Advisors
RETA

Ensign Peak Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ensign Peak Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-126,625
Closed -$12.9M – 1782
2023
Q2 		$12.9M Buy
126,625
+8,250
+7% +$781K 0.03% 361
2023
Q1 		$10.8M Buy
118,375
+47,460
+67% +$2.78M 0.02% 396
2022
Q4 		$2.69M Sell
70,915
-7,200
-9% -$248K 0.01% 723
2022
Q3 		$1.96M Buy
78,115
+15,379
+25% +$426K ﹤0.01% 790
2022
Q2 		$1.91M Buy
62,736
+41,309
+193% +$1.23M ﹤0.01% 823
2022
Q1 		$702K Buy
21,427
+14,847
+226% +$441K ﹤0.01% 1405
2021
Q4 		$174K Buy
+6,580
New +$509K ﹤0.01% 1954
2021
Q3 		– Sell
-11,218
Closed -$1.59M – 1888
2021
Q2 		$1.59M Buy
11,218
+8,947
+394% +$1.01M ﹤0.01% 1240
2021
Q1 		$226K Hold
2,271
– – ﹤0.01% 1716
2020
Q4 		$281K Sell
2,271
-7,372
-76% -$969K ﹤0.01% 1685
2020
Q3 		$939K Buy
9,643
+6,759
+234% +$845K ﹤0.01% 1337
2020
Q2 		$450K Buy
2,884
+560
+24% +$85.1K ﹤0.01% 1484
2020
Q1 		$335K Sell
2,324
-690
-23% -$133K ﹤0.01% 1467
2019
Q4 		$617K Buy
+3,014
New +$550K ﹤0.01% 1483

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ensign Peak Advisors's RETA Position: Q3 2023 in Review

Ensign Peak Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 126,625 shares — an estimated $12.9M sold.

Ensign Peak Advisors first reported a position in RETA in Q4 2019 and held it in 14 quarters. The position peaked at $12.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Ensign Peak Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 126,625 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $12.9M.
  • Ensign Peak Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 14 quarters.
  • Ensign Peak Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $12.9M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.